"We strongly disagree with the conclusions of the Smith Barney report concerning Lipitor," Pfizer spokesman Paul Fitzhenry said. "We believe that our patents for Lipitor are valid and have been infringed by Ranbaxy and we have filed suits accordingly."
Pfizer shares were recently down 99 cents or 3.2%, at $29.75.
-By Hollister H. Hovey, Dow Jones Newswires; 201-938-5287; hollister.hovey@dowjones.com
Market Data 
Markets 
AI
